13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
90 檔
42.6%
The Q3 2024 SEC filing reveals that Sectoral Asset Management Inc held a total portfolio value of $143.3M, covering 90 public equity positions.
In Q3 2024, Sectoral Asset Management Inc adopted a defensive or profit-taking posture, trimming 63 positions and completely liquidating 15 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | Stock-Other | 13.70% | — | -9.88% | |
| 2 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 9.05% | +0.45% | — | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.75% | +0.48% | -53.04% | |
| 4 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 4.53% | +0.49% | -50.80% | |
| 5 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.02% | -1.60% | -11.28% | |
| 6 | JNJ | Johnson & Johnson | Stock-Healthcare | 2.48% | -0.46% | -54.44% | |
| 7 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.36% | -0.47% | -24.90% | |
| 8 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.11% | -1.12% | -43.71% | |
| 9 | PFE | Pfizer Inc | Stock-Healthcare | 1.96% | -0.18% | -36.80% | |
| 10 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.92% | -0.20% | -50.07% | |
| 11 | ABBV | Abbvie Inc | Stock-Healthcare | 1.84% | -0.06% | -64.85% | |
| 12 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.63% | -0.73% | -53.79% | |
| 13 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.61% | -0.20% | -72.25% | |
| 14 | SYK | Stryker CORP | Stock-Healthcare | 1.59% | -0.03% | -42.02% | |
| 15 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.57% | -0.23% | -22.36% | |
| 16 | MDT | Medtronic plc | Stock-Healthcare | 1.56% | -0.19% | -50.71% | |
| 17 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.53% | -0.12% | -10.64% | |
| 18 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.53% | -0.21% | +66.67% | |
| 19 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.46% | — | -1.43% | |
| 20 | BOLD | Boundless Bio Inc | Stock-Other | 1.39% | -0.62% | EXIT | |
| 21 | AMGN | Amgen Inc | Stock-Healthcare | 1.35% | -0.58% | -51.77% | |
| 22 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.33% | -0.98% | -44.05% | |
| 23 | ABT | Abbott Laboratories | Stock-Healthcare | 1.31% | -1.04% | -70.72% | |
| 24 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.28% | -0.44% | -38.72% | |
| 25 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.06% | +0.29% | -51.28% | |
| 26 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.04% | — | +3543.50% | |
| 27 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.01% | -0.21% | +65.18% | |
| 28 | PCVX | Vaxcyte Inc | Stock-Other | 0.98% | — | -56.89% | |
| 29 | CVS | Cvs Health CORP | Stock-Healthcare | 0.95% | +0.94% | NEW | |
| 30 | BNTX | Biontech Se-adr | Stock-Other | 0.92% | +1.03% | -51.75% | |
| 31 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.91% | — | -8.74% | |
| 32 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 0.90% | — | — | |
| 33 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.89% | +0.52% | -22.48% | |
| 34 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.89% | — | -34.82% | |
| 35 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.89% | -0.38% | -43.52% | |
| 36 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.86% | — | -49.34% | |
| 37 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.85% | -0.28% | EXIT | |
| 38 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.84% | -0.39% | -58.37% | |
| 39 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.82% | — | +287.53% | |
| 40 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.81% | — | +27.21% | |
| 41 | DHR | Danaher CORP | Stock-Healthcare | 0.78% | -0.23% | -73.06% | |
| 42 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.78% | — | +1260.00% | |
| 43 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.78% | — | -42.60% | |
| 44 | OPCH | Option Care Health Inc | Stock-Healthcare | 0.74% | — | -38.46% | |
| 45 | BIIB | Biogen Inc | Stock-Healthcare | 0.69% | -0.04% | -1.79% | |
| 46 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.68% | +1.53% | -3.65% | |
| 47 | ARVN | Arvinas Inc | Stock-Other | 0.67% | — | +31.58% | |
| 48 | EVH | Evolent Health Inc - A | Stock-Other | 0.65% | — | -53.57% | |
| 49 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.63% | -0.43% | +82.53% | |
| 50 | NARIUSD | Inari Medical Inc | Stock-Other | 0.61% | — | -38.27% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | +6.1% | -9.88% | Trim |
| 2 | CTNM | Contineum Therapeutics Inc-a | +3.3% | — | Unchanged |
| 3 | GILD | Gilead Sciences Inc | +1.1% | -11.28% | Trim |
| 4 | ZLAB | Zai Lab Ltd-adr | +1% | +3543.50% | Add |
| 5 | BMY | Bristol-myers Squibb Co | +1% | +66.67% | Add |
| 6 | SGOV | Ishares 0-3 Month Treasury B | +0.9% | NEW | New buy |
| 7 | AZNN | Astrazeneca Plc-spons Adr | +0.8% | -1.43% | Trim |
| 8 | LEGN | Legend Biotech Corp-adr | +0.7% | +1260.00% | Add |
| 9 | 2655787D | Blueprint Medicines CORP | +0.7% | +287.53% | Add |
| 10 | NBIX | Neurocrine Biosciences Inc | +0.6% | +218.04% | Add |
| 11 | QURE | uniQure N.V. | +0.5% | NEW | New buy |
| 12 | MLTX | Moonlake Immunotherapeutics | +0.4% | +27.21% | Add |
| 13 | GPCR | Structure Therapeutics Inc | +0.4% | +82.53% | Add |
| 14 | EW | Edwards Lifesciences CORP | +0.4% | +65.18% | Add |
| 15 | ✓ | Engene Holdings Inc | +0.4% | NEW | New buy |
| 16 | RCKT | Rocket Pharmaceuticals Inc | +0.4% | +246.23% | Add |
| 17 | ALNY | Alnylam Pharmaceuticals Inc | +0.3% | -22.36% | Trim |
| 18 | BOLD | Boundless Bio Inc | +0.3% | -0.54% | Trim |
| 19 | ARVN | Arvinas Inc | +0.3% | +31.58% | Add |
| 20 | MLYS | Mineralys Therapeutics Inc | +0.3% | -24.90% | Trim |
| 21 | SMMT | Summit Therapeutics Inc | +0.3% | +6.80% | Add |
| 22 | COGT | Cogent Biosciences Inc | +0.3% | -1.40% | Trim |
| 23 | TARS | Tarsus Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 24 | ONC | Beone Medicines Ltd-adr | +0.2% | +7.76% | Add |
| 25 | SWTXUSD | Springworks Therapeutics Inc | +0.2% | NEW | New buy |
| 26 | ILMN | Illumina Inc | +0.2% | -1.12% | Trim |
| 27 | RCUS | Arcus Biosciences Inc | +0.2% | -3.65% | Trim |
| 28 | BMRN | Biomarin Pharmaceutical Inc | +0.2% | -10.64% | Trim |
| 29 | NVO | Novo-nordisk A/s-spons Adr | +0.2% | NEW | New buy |
| 30 | INSM | Insmed Inc | +0.2% | -1.43% | Trim |
| 31 | ARGX | Argenx Se - Adr | +0.1% | -38.72% | Trim |
| 32 | GERN | Geron CORP | +0.1% | NEW | New buy |
| 33 | CATX | Perspective Therapeutics Inc | +0.1% | +85.45% | Add |
| 34 | PTCT | Ptc Therapeutics Inc | +0.1% | +76.74% | Add |
| 35 | BIIB | Biogen Inc | +0.1% | -1.79% | Trim |
| 36 | ROIV | Roivant Sciences Ltd. | +0.1% | -1.81% | Trim |
| 37 | ITCIEUR | Intra-cellular Therapies Inc | +0.1% | -1.53% | Trim |
| 38 | RPRX | Royalty Pharma plc | +0.1% | -1.32% | Trim |
| 39 | CYTK | Cytokinetics Inc | +0.1% | -22.48% | Trim |
| 40 | VTRS | Viatris Inc | +0.1% | +13.96% | Add |
| 41 | VERA | Vera Therapeutics Inc | +0.1% | -3.76% | Trim |
| 42 | JPST | Jpmorgan Ultra-short Income | +0.1% | NEW | New buy |
| 43 | CRNX | Crinetics Pharmaceuticals In | +0.1% | — | Unchanged |
| 44 | RVMD | Revolution Medicines Inc | +0.1% | -2.58% | Trim |
| 45 | EXEL | Exelixis Inc | +0.1% | -3.93% | Trim |
| 46 | BBIO | Bridgebio Pharma Inc | +0.1% | -2.90% | Trim |
| 47 | KYTX | Kyverna Therapeutics Inc | +0.1% | +227.14% | Add |
| 48 | SRPT | Sarepta Therapeutics Inc | 0% | -8.74% | Trim |
| 49 | ASND | Ascendis Pharma A/S | 0% | -19.69% | Trim |
| 50 | BNTX | Biontech Se-adr | 0% | -51.75% | Trim |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 90 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LENZ, CTNM, LLY) accounted for 42.6% of total reported equity market value during Q3 2024.
Top New Position Initiated
SGOV
市值: $1.5M
Top Position Liquidated / Trimmed
ELV
前期市值: $2.4M
During Q3 2024, Sectoral Asset Management Inc's top holdings by market value included LENZ (13.7%)、CTNM (9.1%)、LLY (5.8%). The largest single position, LENZ, represented 13.7% of total portfolio value.
In Q3 2024, Sectoral Asset Management Inc made 102 total portfolio adjustments, initiating 8 new buys, adding to 16 positions, trimming 63 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.